These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 30099947)

  • 21. US Food and Drug Administration Disruption of Generic Drug Market Increases Hospital Costs.
    Almeter PJ; Labuhn JA; Morris PE; Hessel EA
    Anesth Analg; 2018 Dec; 127(6):1414-1420. PubMed ID: 29944521
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pseudo-Generics in South Africa: A Price Comparison.
    Bangalee V; Suleman F
    Value Health Reg Issues; 2019 Sep; 19():87-91. PubMed ID: 31357098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Generic drug prices fall overall in '94.
    Hosp Mater Manage; 1995 Feb; 20(2):1, 12-3. PubMed ID: 10140171
    [No Abstract]   [Full Text] [Related]  

  • 25. Incentives and disincentives to drug innovation: evidence from recent literature.
    Lee Mendoza R
    J Med Econ; 2019 Aug; 22(8):713-721. PubMed ID: 31038374
    [No Abstract]   [Full Text] [Related]  

  • 26. [Price differences between generic and innovator medicines in Brazil].
    Vieira FS; Zucchi P
    Rev Saude Publica; 2006 Jun; 40(3):444-9. PubMed ID: 16810368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decreasing utilization and increasing prices of brand-name oral contraceptive pills: Implications to societal costs and market competition.
    Zhang JX
    PLoS One; 2020; 15(6):e0234463. PubMed ID: 32525965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generic Drugs in the United States: Policies to Address Pricing and Competition.
    Gupta R; Shah ND; Ross JS
    Clin Pharmacol Ther; 2019 Feb; 105(2):329-337. PubMed ID: 30471089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Projecting future drug expenditures--1997.
    Mehl B; Santell JP
    Am J Health Syst Pharm; 1997 Jan; 54(2):153-61. PubMed ID: 9117803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Projecting future drug expenditures--1996.
    Santell JP
    Am J Health Syst Pharm; 1996 Jan; 53(2):139-50. PubMed ID: 8653479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Do generics offer significant savings to the UK National Health Service?
    Kanavos P
    Curr Med Res Opin; 2007 Jan; 23(1):105-16. PubMed ID: 17257472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmaceuticals and Medical Devices: Cost Savings.
    Steiner DJ;
    Issue Brief Health Policy Track Serv; 2017 Dec; 2017():1-31. PubMed ID: 29361657
    [No Abstract]   [Full Text] [Related]  

  • 33. Examining the production costs of antiretroviral drugs.
    Pinheiro E; Vasan A; Kim JY; Lee E; Guimier JM; Perriens J
    AIDS; 2006 Aug; 20(13):1745-52. PubMed ID: 16931939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-cost generic drugs--implications for patients and policymakers.
    Alpern JD; Stauffer WM; Kesselheim AS
    N Engl J Med; 2014 Nov; 371(20):1859-62. PubMed ID: 25390739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Why drug prices will go lower.
    Tully S
    Fortune; 1993 May; 127(9):56-8, 60, 62 passim. PubMed ID: 10125261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic and technological drivers of generic sterile injectable drug shortages.
    Woodcock J; Wosinska M
    Clin Pharmacol Ther; 2013 Feb; 93(2):170-6. PubMed ID: 23337525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Policies encouraging price competition in the generic drug market: Lessons from the European experience].
    Puig-Junoy J
    Gac Sanit; 2010; 24(3):193-9. PubMed ID: 20189690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of price-cap regulations on market entry by generic pharmaceutical firms.
    Zhang W; Sun H; Guh D; Anis AH
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):231-238. PubMed ID: 27936981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High Prices for Drugs With Generic Alternatives: The Curious Case of Duexis.
    Hakim A; Ross JS
    JAMA Intern Med; 2017 Mar; 177(3):305-306. PubMed ID: 28114637
    [No Abstract]   [Full Text] [Related]  

  • 40. Inflated medicine prices in Vietnam: a qualitative study.
    Nguyen TA; Knight R; Mant A; Razee H; Brooks G; Dang TH; Roughead EE
    Health Policy Plan; 2017 Jun; 32(5):647-656. PubMed ID: 28453716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.